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ical functions that include induction of apoptosis, inhibition of
angiogenesis, and immunomodulation. We have demonstrated
that intratumoral injection of an IFN-a-expressing adenovirus
effectively induces cell death of cancer cells and elicits a systemic
tumor-specific immunity in several animal models. On the other
hand, reports demonstrated that an elevation of IFN in the serum
following an intramuscular delivery of a vector is able to activate
antitumor immunity. In this study, we compared the intratumoral
and systemic routes of IFN gene transfer with regard to the effect
and safety of the treatment. Intratumoral injection of an IFN-a ade-
novirus effectively activated tumor-responsive lymphocytes and
caused tumor suppression not only in the gene-transduced tumors
but also in distant tumors, which was more effective than the
intravenous administration of the same vector. The expression of
co-stimulatory molecules on CD11c+ cells isolated from regional
lymph nodes was enhanced by IFN gene transfer into the tumors.
Systemic toxicity such as an elevation of hepatic enzymes was
much lower in mice treated by intratumoral gene transfer than in
those treated by systemic gene transfer. Our data suggest that the
intratumoral route of the IFN vector is superior to intravenous
administration, due to the effective induction of antitumor immu-
nity and the lower toxicity. (Cancer Sci 2010; 101: 1686–1694)
I nterferon-alpha (IFN-a) belongs to the group of type I inter-ferons. It is produced by monocytes ⁄macrophages, lympho-
blastoid cells, fibroblasts, and plasmacytoid dendritic cells.
Interferon-alpha (IFN-a) binds to the IFN-a receptor CD118,
and the IFN receptor is coupled to a Janus-family tyrosine
kinase, which phosphorylates signal-transducing activators of
transcription (STATs), and STATs translocate to the nucleus
where they activate the transcription of several different genes
including the synthesis of host cell proteins that contribute to
the inhibition of viral replication.(1) In addition to its antiviral
activity, IFN-a exhibits several other antitumor functions:
(i) direct inhibitory effects on tumor cell growth; (ii) radio and
chemosensitizing effects; (iii) anti-angiogenic properties; and
(iv) modulation of the immune system.(2–5) These features
might be of special interest for use in cancer treatments.
Among the above antitumor properties, the direct inhibitory
effects on tumor cell growth ⁄ functions and the interaction of
IFN-a with chemotherapeutic drugs such as 5-FU have been
of particular interest.(2,3) The cytokine has been used world-
wide for treatment of a variety of cancers including chronic
myelogeneous leukemia, melanoma, and renal cancer.(2,5)
However, clinical experiences with IFN protein therapy for
many other solid cancers have generally not been encourag-
ing.(6) In the conventional regimen of IFN clinical trials, theCancer Sci | July 2010 | vol. 101 | no. 7 | 1686–1694recombinant IFN-a protein is systemically administered
through subcutaneous or intramuscular routes. Since the pro-
tein is rapidly degraded in the blood circulation and only a
small portion of subcutaneously injected IFN-a can reach the
target sites,(7) the overall limited therapeutic efficacy of treat-
ments based on the IFN-a protein may reflect the inability to
target the cytokine to the right place and at the right dose.
Alternative delivery strategies are needed to achieve a safe
and effective IFN delivery in a clinical setting. In fact, it was
reported that gene- and cell-based delivery of type I IFNs into
tumors suppressed growth of various cancers such as breast
cancer, prostate cancer, renal cancer, hepatocellular carcinoma,
basal cell carcinoma, bladder cancer, and leukemia.(8–13) We
have also shown that a single injection of the recombinant
IFN-a protein into a tumor did not result in the suppression of
tumor growth, whereas an intratumoral injection of an IFN-a-
expressing adenovirus effectively induced cell death of cancer
cells and did suppress the growth of tumors including pancre-
atic, colon, and renal cancers.(14–17)
Type I IFNs were long thought to act mainly by suppressing
tumor cell proliferation in vivo. However, more recently, it has
been established that type I IFNs have important roles in regu-
lating innate and adaptive arms of the immune system: up-regu-
lation of major histocompatibility complex (MHC) class I gene,
promotion of the priming and survival of T cells, enhancement
of humoral immunity, increase of the cytotoxic activity of natu-
ral killer (NK) cells and CD8+ T cells, and activation of den-
dritic cells (DCs).(4,5) We have also shown that in addition to
the direct cytotoxicity in the injected site, intratumoral injection
of the IFN-a adenovirus elicits a significant systemic tumor-
specific immunity in several animal models.(15,16) On the other
hand, it has been reported that an intramuscular delivery of the
IFN-a gene exhibited inhibition of tumor growth and that CD8+
T cells were required for the antitumor response,(18,19) suggest-
ing that an elevation of the IFN-a level in the serum also acti-
vates the antitumor immunity. However, it has not been
examined whether the high IFN-a level in the tumor and blood
circulation effectively induces antitumor immunity. It is diffi-
cult to inject high amounts of the IFN-a adenovirus into the
muscle of mice without a leakage of the vector into the blood
circulation, which may result in a variety of serum IFN-a levels
among mice injected with the same amounts of IFN-a vector.
Therefore, in this study, the adenovirus was injected into the
tail vein to express consistent IFN-a at a high sustained level in
the serum, and the antitumor immunity and safety were com-
pared between the intratumoral and systemic routes of IFN gene
transfer.doi: 10.1111/j.1349-7006.2010.01578.x
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Materials and Methods
Tumor cell line and recombinant adenovirus vectors. CT26
and Renca are weakly immunogenic BALB ⁄ c-derived colon and
renal cancer cell lines, respectively, which were obtained from
the American Type Culture Collection (Rockville, MD, USA).
CT26 and Renca cells were confirmed to express MHC class I
molecules (H-2Kd and H-2Dd) by flow cytometry; however, the
heterogeneous MHC expression was observed in the subcutane-
ous tumors (data not shown). Cells were maintained in RPMI
containing 10% FBS, 2 mM L-glutamine, and 0.15% sodium
bicarbonate (complete RPMI). The recombinant adenovirus
vectors expressing mouse interferon-a (Ad-mIFN) or alkaline
phosphatase (Ad-AP) were prepared as described.(15,20) The
recombinant adenoviruses are based on the serotype 5 with a
deletion of the entire E1 region and a part of the E3 region, and
have the CAG promoter, which is a hybrid of the cytomegalovi-
rus immediate early enhancer sequence and the chicken
b-actin ⁄ rabbit b-globin promoter, in the deleted E1 region.(21)
A cesium chloride-purified virus was desalted using a sterile
Bio-Gel P-6 DG chromatography column (Econopac DG 10;
BioRad, Hercules, CA, USA) and diluted for storage in a 13%
glycerol ⁄PBS solution. All viral preparations were free of the
E1+ adenovirus by PCR assay.(22)
In vivo tumor inoculation and IFN-a gene transfer. Tumor
cells were prepared in a total volume of 100 lL PBS (5 · 106 of
Renca and 1 · 106 of CT26 cells) and injected subcutaneously
into the leg of BALB ⁄ c mice (Charles River Japan, Kanagawa,
Japan). When the subcutaneous tumor was established (0.5 cm
in diameter), 50 lL of Ad-mIFN or control vector (Ad-AP) was
injected once into the tumors or into the tail vein. The injection
of 1 · 108 PFU (plaque forming unit) of Ad-AP showed that
70–80% of the cells were stained in the entire CT26 tumors. The
shortest (r) and longest (l) tumor diameters were measured and
the tumor volume was determined as r2 · l ⁄2.
To deplete NK cells before and during the treatment with
IFN-a gene transfer, BALB ⁄ c nude mice (Charles River Japan)
received intraperitoneal injections of 0.5 mg of anti-asialo GM1
antibody targeting NK cells (Wako Pure Chemical Industries,
Tokyo, Japan). Administration of antibody started 2 days after
the inoculation of CT26 cells, and the injection was repeated
every 5–6 days throughout the entire experimental period. Flow
cytometry showed that more than 80% of NK cells were
depleted in the antibody-treated mice.
Reverse transcription–polymerase chain reaction (RT-PCR) and
ELISA analyses of IFN-a expression. Subcutaneous tumors were
collected 4 days after the intratumoral or intravenous injection
of Ad-mIFN or Ad-AP in the CT26 tumor-bearing BALB ⁄ c
mice. To examine the expression of the IFN-a gene in the
tumors, RT-PCR amplification was carried out using total RNA
in a 50 lL of the PCR mixture with the following primer sets:
IFN-a upstream (5¢-GATGGTTCTGGCTGTGATGAG-3¢) and
downstream (5¢-GATGTTCAGGATCTGCTGGGT-3¢) primers;
b-actin upstream (5¢-CCTCTATGCCAACACAGTGC-3¢) and
downstream (5¢-ATACTCCTGCTTGCTGATCC-3¢) primers. In
total, 33 cycles (b-actin, 25 cycles) of the PCR were carried out
at 94C for 1 min, 60C for 1 min, and 72C for 2 min. The
PCR products were electrophoresed on a 2% agarose gel. Inter-
feron-alpha (IFN-a) concentration in the serum, tumor and
organs was measured by enzyme-linked immunosorbent assay
(ELISA; Immunotech, Marseille Cedex, France).
ELISpot assays. Interferon-gamma (IFN-c) ELISpot kits (BD
Bioscience, San Jose, CA, USA) were used according to the
manufacturer’s instructions. CT26 cells were inoculated into the
BALB ⁄ c mice, and 7 days later 1 · 108 PFU of Ad-mIFN or
Ad-AP was administered into the tumors or into the tail vein.
Twenty days later, splenocytes were harvested from the mice,
and the splenocytes (1 · 105) and mitomycin C (MMC)-treatedNarumi et al.CT26 cells (1 · 104) were co-cultured for 20 h at 37C in com-
plete RPMI medium in 96-well plates pre-coated with antimouse
IFN-c antibody (BD Bioscience) in triplicate. After aspirating
the cells away and washing the wells with de-ionized water, a
biotinylated antimouse IFN-c antibody (2 lg ⁄mL) was added
and incubated for 2 h at room temperature. After extensive
washing, a streptavidin–horseradish peroxidase solution was
added and incubated for 1 h at room temperature. Then, an
aminoethyl carbazole substrate solution was added, and the plate
was incubated for 15 min. Spots were counted under a stereomi-
croscope.
Flow cytometry of co-stimulatory molecules. The regional
lymph nodes were collected from the CT26 tumor-bearing mice
10 days after the intratumoral or intravenous injection of
Ad-mIFN or Ad-AP (1 · 108 PFU). The 1 · 106 of cells from
the lymph nodes were incubated at 4C for 30 min with phyco-
erythrin-conjugated hamster antimouse CD11c monoclonal
antibody (HL3; IgG; BD Biosciences), FITC-conjugated rat an-
timouse CD40 monoclonal antibody (3 ⁄23; IgG; BD Bioscienc-
es), FITC-conjugated hamster antimouse CD80 monoclonal
antibody (16-10A1; IgG; BD Biosciences), FITC-conjugated rat
antimouse CD86 monoclonal antibody (GL1; IgG; BD Bio-
sciences), or isotype control antibody (IgG), and then washed
twice with PBS containing 2% BSA. Flow cytometry was car-
ried out using a FACScan system (BD Bioscience).
Immunohistochemistry. Immunostaining was performed
using the streptavidin–biotin–peroxidase complex techniques
(Nichirei, Tokyo, Japan). Consecutive cryostat tissue sections
(5 lm) were mounted on glass slides and fixed in 99.5% ethanol
for 20 min. After blocking with normal rat serum, the sections
were stained with rat antimouse CD4 and CD8 antibodies (BD
Biosciences). The cryostat sections were also processed for the
terminal deoxynucleotidyltransferase-mediated dUTP-digoxige-
nin nick-end-labeling (TUNEL) assay (Intergen Company, Pur-
chase, NY, USA). Negative controls without primary antibodies
were examined in all cases. The sections were counterstained
with methylgreen.
Statistical analysis. Two-sided t-tests were used to validate
the significance of the observed differences, which were consid-
ered statistically significant when P < 0.05.
Results
Distribution of interferon-a in various organs following
intratumoral or intravenous administration of Ad-mIFN. To con-
firm the in vivo expression of the IFN-a gene, total RNA of
CT26 subcutaneous tumors was subjected to an RT-PCR analy-
sis of the gene 4 days after the intratumoral or intravenous injec-
tion of Ad-mIFN or control Ad-AP (1 · 108 PFU). Intratumoral
IFN-a gene transfer yielded a significant level of IFN-a expres-
sion in the tumor, whereas the intravenous route did not show
the IFN-a band there (Fig. 1a). The IFN-a expression was not
detected in the tumor injected with Ad-AP (Fig. 1a).
To determine the kinetics of IFN-a expression in the serum,
the IFN-a levels were measured 3, 4, 7, and 13 days after the
intratumoral or intravenous injection of Ad-mIFN. In the mice
treated by intratumoral IFN-a gene transfer, the cytokine was
slightly elevated at Day 3 and returned to a base line by Day 4,
whereas in the mice with the intravenous injection of Ad-mIFN
the peak levels in the serum were observed at Day 3 and the
expression continued for more than 13 days, demonstrating that
the intravenous gene transfer leads to the sustained high IFN-a
expression in the blood circulation (Fig. 1b).
Then, to examine the in vivo distribution of IFN-a expression,
we inoculated CT26 cells into both legs of BALB ⁄ c mice, fol-
lowed by adenovirus (1 · 108 PFU) injection either into the
right tumors or into the tail veins. Three days later the IFN-a
levels were measured in the serum, subcutaneous tumors, andCancer Sci | July 2010 | vol. 101 | no. 7 | 1687




Fig. 1. Distribution of interferon-alpha (IFN-a) in the sera,
subcutaneous tumors, and various organs. (a) Expression of IFN-a gene
in subcutaneous tumors. The 1 · 108 PFU (plaque forming unit) of
recombinant adenovirus vectors expressing mouse interferon-a
(Ad-mIFN) or alkaline phosphatase (Ad-AP) was injected into the CT26
subcutaneous tumor or into the tail vein, and 4 days later the
subcutaneous tumor was isolated, and IFN-a expression was examined
by RT-PCR analysis. (b) Time course of IFN-a expression in the serum.
The 1 · 108 PFU of Ad-mIFN was injected into the subcutaneous
tumor or into the tail vein, and IFN-a concentration in the serum was
measured by ELISA 3, 4, 7, and 13 days after the injection (n = 4). iv,
intravenous injection; it, intratumoral injection. (c) Interferon-alpha
(IFN-a) concentration in the sera, tumors, and organs. The 1 · 108 PFU
of adenoviruses was injected into the subcutaneous tumor or into the
tail vein, and 3 days later IFN-a concentration was measured (n = 4).
Rt, right; Lt, left.various organs such as the spleen, liver, kidney, and lung. In the
mice treated by intratumoral IFN-a gene transfer, the serum
showed a slight elevation of IFN-a, whereas its concentration1688was highest in the right virus-injected tumor (Fig. 1c), which
was approximately 10-fold higher than the serum as previously
described.(14,15,17,23) In the mice treated by intravenous IFN-a
gene transfer, the IFN-a level was significantly elevated in the
serum and various organs including the liver but not in the sub-
cutaneous tumors compared with the intratumoral IFN-a gene
transfer (Fig. 1c). The IFN-a was not elevated in the serum,
tumors, or organs in the mice that received the administration of
Ad-AP.
Antitumor effects of intratumoral and intravenous adminis-
tration of Ad-mIFN. To examine the in vivo antitumor effect of
the IFN-a gene transduction, various amounts (5 · 106, 5 · 107,
1 · 108, and 5 · 108 PFU) of adenoviruses were injected into
right tumors or into the tail veins in mice with CT26 tumors on
both legs. The intravenous injection of Ad-mIFN did not show a
definite suppressive effect except at the highest dose examined
(5 · 108 PFU), which resulted in tumor suppression comparable
with that of the intratumoral injection (Fig. 2a). The intratumor-
al injection of Ad-mIFN showed remarkable tumor suppressive
effects in not only the vector-injected right tumors but also in
the vector-uninjected left tumors at all doses examined
(Fig. 2a,b). Tumor volumes were not changed in the mice trea-
ted by intratumoral and intravenous injections of Ad-AP at any
doses (Fig. 2a), which were similar to those in the no treatment
group (data not shown).
To compare the IFN-a levels in the tumors with the antitumor
effects, an IFN-a concentration was examined 3 days after the
gene transfer. The IFN-a concentration in the tumors following
the intratumoral gene transfer was elevated in a dose-dependent
manner, and the levels were much higher than those for the
intravenous injections at all doses (Fig. 2c). An intravenous
injection of less than 1 · 108 PFU of Ad-mIFN did neither ele-
vate the IFN-a concentration in the tumors nor suppress the
tumor growth. By contrast, the intravenous injection of the high
dose (5 · 108 PFU) resulted in 1522.2 pg ⁄g of IFN-a in the
tumors, which was close to that (2054.7 pg ⁄g) after an intra-
tumoral injection of low dose (5 · 106 PFU) of Ad-mIFN
(Fig. 2c), and significantly suppressed tumor growth (Fig. 2a).
The increase of the IFN-a level in the tumor might be related to
induction of an effective antitumor immunity.
To confirm the antitumor activity of intratumoral IFN-a gene
transfer in a different tumor cell line, 1 · 108 PFU of Ad-mIFN
was injected into Renca tumor-bearing mice. The antitumor
activity of an intratumoral injection was also evident against the
renal cancer cells (Fig. 2d), and resulted in a statistically signifi-
cant improvement in the survival of the treated mice as com-
pared with the Ad-AP-injected animals (Fig. 2e).
Then, we inoculated CT26 cells on the right legs and on the
backs and Renca cells on the left legs of BALB ⁄ c mice, and
1 · 108 PFU of Ad-mIFN was injected into CT26 tumors on the
right legs. Interferon-alpha (IFN-a) gene transfer suppressed the
growth of not only the right leg CT26 tumors but also the back
CT26 tumors; and the growth of Renca tumors, which were not
transduced with IFN-a gene, on the left legs was also signifi-
cantly suppressed compared with the Ad-AP injection (Fig. 2f).
Certain tumor-associated antigens (TAAs) might be shared by
CT26 and Renca tumors. Alternatively, the activation of NK
cells by the IFN-a expression may be responsible for this
phenomenon as later described.
Cell-death induction and infiltration of CD4+ and CD8+ cells in
the tumors. To examine whether the IFN-a expression induces
cell death in the tumors, TUNEL assay was performed using
tumors of mice treated by IFN-a gene transfer. The assay
revealed massive cell death of cancer cells in Ad-mIFN-injected
tumors as shown in our previous reports,(17) but TUNEL-
positive cells were also recognized albeit relatively sparsely in
the vector-uninjected tumors in the mice treated by intratumoral
IFN-a gene transfer (Fig. 3a). The difference in numbers ofdoi: 10.1111/j.1349-7006.2010.01578.x







Narumi et al.TUNEL-positive cells is probably due to presence of the direct
cell-death induction by the IFN-a expression in the injected but
not uninjected tumors.
To determine whether the different therapeutic efficacies
between the intratumoral and intravenous IFN-a gene transfer
are associated with different T-cell responses, we analyzed the
infiltration of CD4+ and CD8+ cells into the subcutaneous
tumors by immunostaining 10 days after the vector injection.
The intratumoral IFN-a expression significantly increased the
infiltration of CD4+ and CD8+ T cells in the tumors on both legs,
compared to the intravenous administration of Ad-mIFN
(Fig. 3a,b). No increases of those cells were observed in the
Ad-AP-treated mice. The infiltrated immune cells could induce
an antitumor effect against tumors, in particular at distant sites.
Natural killer (NK) cells also play a role in antitumor effect of
intratumoral Ad-mIFN administration. It has been reported that
IFN-a enhances the activity of NK cells(4) in addition to the acti-
vation of cytotoxic T lymphocyte. To determine whether the
absence of T cells abrogates IFN-a-mediated therapeutic effi-
cacy, we inoculated CT26 cells in both legs of BALB ⁄ c nude
mice, and then injected 5 · 107 PFU of Ad-mIFN into the tumor
on the right leg or into the tail vein. The intravenous IFN-a gene
transfer showed modest tumor growth inhibition compared with
the Ad-AP injection, whereas a marked suppression of both vec-
tor-injected and vector-uninjected tumors was observed after
intratumoral IFN-a gene transfer (Fig. 4a). The depletion of NK
cells with anti-asialo GM1 antibody cancelled the antitumor
effect of vector-uninjected tumors on the left legs almost com-
pletely, whereas significant growth suppression was still recog-
nized in the Ad-mIFN-injected tumors on the right legs
(Fig. 4b), possibly due to the direct cell-death induction by IFN-
a expression. The results suggest that the NK cells in the regio-
nal tumor are activated by the IFN-a expression and contribute
to systemic antitumor immunity, which is consistent with our
previous report.(15) Interestingly, the intravenous injection of
5 · 107 PFU of Ad-mIFN suppressed the tumor growth in
immune-deficient nude mice (Fig. 4a) but not in immune-com-
petent mice (Fig. 2b). The difference may be explained by theFig. 2. Intratumoral interferon-alpha (IFN-a) gene transfer induces a
systemic antitumor effect. CT26 cells were inoculated in both legs in
BALB ⁄ c mice, and 7 days later recombinant adenovirus vectors
expressing mouse interferon-a (Ad-mIFN) or alkaline phosphatase (Ad-
AP) was injected into the subcutaneous tumor on the right leg or into
the tail vein. (a) Growth suppression of the CT26 subcutaneous tumors
20 days after the tumor inoculation. Various amounts (5 · 106,
5 · 107, 1 · 108, and 5 · 108 PFU [plaque forming unit]) of
adenoviruses were injected, and 13 days after the virus injection
tumor volume was measured (n = 6). In the mice treated by
intravenous injection of adenoviruses, tumor volumes on both legs
were combined to calculate the average. (b) Time course of CT26
tumor growth following intratumoral IFN-a gene transfer. The
5 · 107 PFU of adenoviruses was injected, and tumor volume was
measured at indicated days (n = 6). (c) Interferon-alpha (IFN-a) levels
after the injection of various amounts of Ad-mIFN. Various amounts
of Ad-mIFN were injected into the subcutaneous tumor or into the
tail vein, and 3 days later IFN-a concentration was measured in the
serum and tumor (n = 3). The IFN-a concentration in the tumors
injected with 5 · 108 PFU of Ad-mIFN was 13895.3 ± 5916.1 pg ⁄ g. (d)
Time course of Renca tumor growth. The 1 · 108 PFU of adenoviruses
was injected, and tumor volume was measured at indicated days
(n = 4). In the mice treated by intravenous injection of adenoviruses,
tumor volumes for both legs were combined to calculate the average.
(e) Survival of mice treated by intratumoral or intravenous injection
of adenoviruses. The 1 · 108 PFU of adenoviruses was injected in the
Renca tumor-bearing mice, and a time to death after tumor
inoculation was assessed (n = 6). (f) Growth suppression of CT26 and
Renca tumors. CT26 cells were inoculated on the right legs and on the
backs and Renca cells were inoculated on the left legs in BALB ⁄ c mice,
and then 1 · 108 PFU of Ad-mIFN was injected into the CT26 tumor
on the right leg (n = 6).
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fact that activity of NK cells is more elevated in nude mice com-
pared with immune-competent mice, and by the possibility that
an increase of the serum IFN-a concentration effectively
enhances the cytotoxicity of the NK cells more than that of T
cells. Although it could be due to augmented IFN-a production
since nude mice have less ability to exclude adenovirus,
the serum IFN-a concentration of nude mice 4 days after
the intravenous injection of Ad-mIFN (1 · 108 PFU) was
5444.1 ± 244.7 pg ⁄mL, which was not significantly different
from the value (7402.9 ± 1912.1 pg ⁄mL) of BALB ⁄ c mice
(Fig. 1b).
Expansion of tumor-responsive lymphocytes after intratumoral
IFN-a gene transfer. To examine the expansion of tumor-
responsive lymphocytes after intratumoral or intravenous IFN-a
gene transfer in immune-competent BALB ⁄ c mice, the spleno-
cytes were harvested 20 days after the vector administration,
and stimulated with MMC-treated CT26 cells or syngeneic lym-
phocytes. ELISpot assay showed that the intravenous IFN-a
gene transfer slightly increased the number of IFN-c-secreting
cells in response to CT26 cells compared with the control Ad-
AP injection, and that the intratumoral IFN-a gene transfer
resulted in a significantly higher number of IFN-c-positive spots
than the intavenous injection (Fig. 5a, left), suggesting that the
IFN-a expression in the tumor effectively expanded tumor-
responsive immune cells including cytotoxic T cells and NK
cells. Spot numbers of lymphocytes from CT26 tumor-bearing
mice with no treatment were similar to those with the Ad-AP
injection (data not shown). Intratumoral IFN-a gene transfer did
not significantly change the number of IFN-c-positive spots for
syngeneic lymphocytes, whereas the intravenous route of the
same vector increased the number of spots for lymphocytes
(Fig. 5a, right). The elevation of the IFN-a concentration in the
serum may enhance the lymphocyte reactivity nonspecifically.(a)
(b)
1690Antigen presentation by DCs isolated from vector-injected
tumors. After antigen capture, and in response to inflammatory
stimuli, DCs mature and migrate to lymph nodes to initiate
immunity. To verify whether the expression of IFN-a in the
tumors augments the maturation of the antigen presenting cells,
we isolated CD11c+ cells from the regional lymph nodes of
tumor-bearing mice treated with adenoviruses, and examined
the expression of co-stimulatory molecules in the cells. Flow
cytometry showed that the frequency of CD11c+ cell per lym-
phocyte increased and the expressions of CD40, CD80, and
CD86 were up-regulated in CD11c+ cells isolated from the mice
treated by intratumoral IFN-a gene transfer. The expression of
CD86 in CD11c+ cells after intravenous injections of Ad-mIFN
was slightly increased compared with the Ad-AP-injected mice
(Fig. 5b). The results indicate that IFN-a expression in the
tumor effectively enhances the maturation of CD11c+ cells in
the regional lymph nodes more than the high systemic level of
IFN-a does.
Then, to examine whether the enhanced expression of
co-stimulatory molecules on DCs is associated with antigen pre-
sentation, CD4+ T cells derived from the spleen of CT26 tumor-
bearing control mice were co-cultured for 3 days with the
CD11c+ cells isolated from the tumors in the vector-treated mice
and MMC-treated CT26 cells. The production of IFN-c protein
from the isolated CD11c+ cells per se was minimal in the
in vitro culture (data not shown). ELISpot analysis showed that
a primary culture with CD11c+ cells isolated from the tumors
treated by Ad-mIFN resulted in a higher number of IFN-c-
secreting CD4+ T cells than cultures with CD11c+ cells isolated
from tumors in the intravenously Ad-mIFN-, intratumorally
Ad-AP-, and intravenously Ad-AP-injected mice (Fig. 5c), dem-
onstrating that the antigen presentation capacity of DCs was
significantly enhanced by IFN-a expression in the tumor.Fig. 3. Infiltration of CD4+ and CD8+ T cells into
the tumors. (a) Immunohistochemical staining of
CT26 tumors. Ten days after the administration
of adenoviruses, the fresh frozen sections of
subcutaneous tumors were processed for
immunohistochemistry with anti-CD4 and anti-CD8
antibodies, and also processed for TUNEL staining
(·400). Ab, antibody; H&E, hematoxylin–eosin. (b)
Number of CD4+ and CD8+ T cells in CT26 tumors.
Positive cells were counted in 10 representative
high power view fields (HPF, ·400) under
microscope.
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(a)
(b)
Fig. 4. Suppression of CT26 tumors in nude mice. (a) The CT26 cells
were inoculated on both legs of BALB ⁄ c nude mice, and 7 days later
5 · 107 PFU (plaque forming unit) of recombinant adenovirus vectors
expressing mouse interferon-a (Ad-mIFN) or alkaline phosphatase (Ad-
AP) was injected into the right tumor or into the tail vein. (b) BALB ⁄ c
nude mice were treated with anti-asialo GM1 antibody, and the CT26
tumors were injected with 5 · 107 PFU of Ad-mIFN (n = 7). Tumor
volumes 10 days after interferon-alpha (IFN-a) gene transfer are
presented.
Fig. 5. Activation of antigen-presenting cells isolated from the mice
treated by interferon-alpha (IFN-a) gene transfer. (a) Expansion of
tumor-responsive T cells after intratumoral injection of recombinant
adenovirus vector expressing mouse interferon-a (Ad-mIFN). ELISpot
assay of interferon-gamma (IFN-c)-producing cells was performed in
response to stimulation of CT26 cells. Ad-mIFN or recombinant
adenovirus vector expressing alkaline phosphatase (Ad-AP) was
injected into the CT26 tumor or into the tail vein and 20 days later
splenocytes were co-cultured with CT26 cells or lymphocytes, and
stained with biotinylated antimouse IFN-c antibody to detect captured
IFN-c (n = 3). Lymphocytes were isolated from the spleen of a naı¨ve
BALB ⁄ c mouse. (b) Expression of co-stimulatory molecules on CD11c+
cells. Flow cytometry of CD40, CD80, and CD86 expressions was
performed on CD11c+ cells isolated from regional lymph nodes of the
mice treated by intratumoral or intravenous injection of Ad-mIFN or
Ad-AP (n = 3–4). The frequency of CD11c+ cells (upper left) per
lymphocytes, and CD40+ (upper right), CD80+ (lower left), and CD86+
(lower right) cells per CD11c+ cells are presented. (c) Number of IFN-c-
producing cells by the stimulation of CD11c+ cells. CD11c+ cells were
isolated from the tumors of treated mice. CD4+ T cells were isolated
from the spleens of CT26 tumor-bearing mice, and co-cultured with
CT26 cells and the isolated CD11c+ cells for 3 days, and then the
number of IFN-c-producing CD4+ T cells was counted. AP-CD11c+,
CD11c+ cells isolated from tumors in mice treated by Ad-AP. mIFN-
CD11c+, CD11c+ cells isolated from tumors in mice treated by
Ad-mIFN.
Narumi et al.Lower systemic toxicity after intratumoral injection of Ad-mIFN. To
compare the toxicity between the administration routes of the
IFN-a vector, different doses (1 · 108, 5 · 108, 1 · 109, and
3 · 109 PFU) of Ad-mIFN or Ad-AP were injected into the sub-
cutaneous tumors or into the tail veins of mice. All three mice
treated by intravenous injection of 3 · 109 PFU of Ad-mIFN
died within 4 days after the vector administration, whereas all
the mice treated by the intratumoral injection of the same
amount of Ad-mIFN survived and appeared healthy up to(a)
(b)
(c)
Cancer Sci | July 2010 | vol. 101 | no. 7 | 1691
ª 2010 Japanese Cancer Association
Fig. 6. Elevation of hepatic enzymes after
intravenous injection of recombinant adenovirus
vector expressing mouse interferon-a (Ad-mIFN).
Different doses (1 · 108, 5 · 108, 1 · 109, and
3 · 109 PFU) of Ad-mIFN or recombinant adenovirus
vector expressing alkaline phosphatase (Ad-AP)
were injected into the subcutaneous tumor or
into the tail vein. Five days later the selected
blood chemistries (albumin, creatinine, aspartate
aminotransferase (AST), and alanine aminotrans-
ferase (ALT)) were examined (n = 3).
Table 1. Summary of antitumor effects and toxicities by intratumoral
and intravenous injection of Ad-mIFN at various doses
Route Dose Antitumor effect Toxicity
Intratumoral injection 5 · 106 ++ NE
5 · 107 ++ NE
1 · 108 ++ –
5 · 108 ++ NE
1 · 109 NE –
3 · 109 NE +
Intravenous injection 5 · 106 – NE
5 · 107 – NE
1 · 108 – –
5 · 108 ++ +
1 · 109 NE +++
3 · 109 NE +++
Antitumor effect was evaluated on the basis of tumor growth
compared with recombinant adenovirus vector expressing alkaline
phosphatase (Ad-AP)-injected tumors: +, >70%; ++, 30–70%; +++,
<30%. Toxicity was evaluated on the basis of the elevation of
aspartate aminotransferase (AST) or alanine aminotransferase (ALT)
values compared with average in normal mice: +, >5-fold elevation;
++, 5–100-fold elevation; +++, >100-fold elevation or death. Ad-mIFN,
recombinant adenovirus vector expressing mouse interferon-a;
NE, not evaluated.5 days, when the mice were sacrificed to evaluate serum
enzyme values. In the mice that received the intravenous IFN-a
gene transfer, the injection of 1 · 109 PFU significantly ele-
vated the aspartate aminotransferase (AST) and alanine amino-
transferase (ALT) levels (more than 100-fold higher than the
average value in normal mice) in the serum, and the injection of
5 · 108 PFU slightly elevated the ALT level (5.7-fold higher
than the average value) (Fig. 6). Although the intratumoral
injection of Ad-mIFN slightly increased the AST level in a
dose-dependent manner, the values were similar to the intratu-
moral injection of Ad-AP, confirming the lower systemic toxi-
city after the intratumoral IFN-a gene transfer. Regarding
albumin and creatinine, there was no significant difference
among the treated mice (Fig. 6).
Discussion
It has been reported that the modes of antitumor responses of
IFN-a gene therapy manifested three aspects: direct antiprolifer-
ative effect,(1) stimulation of antitumor immunity,(4) and anti-
angiogenesis activity.(24) Our previous reports also showed that
an intratumoral IFN-a gene transfer induces a marked regional
antitumor effect and an effective systemic immunity.(15,16) This
immunity was not attributable to the elevated level of the IFN-a
in the systemic circulation, because we found a little leakage of
the cytokine following the intratumoral injection of the IFN-
expressing adenovirus.(15,17) On the other hand, the elevation of
the systemic IFN-a level after intramuscular delivery of the
IFN-a gene was reported to exhibit an inhibition of tumor
growth by the infiltration of CD8+ T cells.(18,19) Therefore, in
this study, we compared the induction of systemic antitumor
immunity by a high IFN-a level in the tumor and blood circula-
tion. The antitumor effects and general toxicities in the mice
treated by intratumoral or intravenous injection of Ad-mIFN at
various doses are summarized in Table 1. The tumor growth
suppression was recognized at the lowest dose (5 · 106 PFU)
and the toxicity was not observed at levels of less than
1 · 109 PFU in the mice treated by the intratumoral IFN-a gene1692transfer, whereas the antitumor effect only appeared at
5 · 108 PFU, and hepatic toxicity was observed at the
5 · 108 PFU level, in the mice treated by intravenous gene
transfer. The results suggested that the intratumoral route of IFN
vector is superior to intravenous administration, due to the effec-
tive induction of an antitumor immunity and the lower toxicity.
The underlying mechanism of the antitumor immunity
induced by IFN-a gene transfer is not fully understood. In this
study, we noticed the role of IFN-a in the maturation and func-
tion of DCs. Dendritic cells (DCs) are antigen-presenting cells
specialized to induce T-cell responses against cells exposingdoi: 10.1111/j.1349-7006.2010.01578.x
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foreign peptides including TAAs, and DCs show an effective
cross-priming with antigens from apoptotic tumor cells.(25,26) As
shown in Figure 3a and our previous report,(17) a high IFN-a
level after intratumoral injection of an adenovirus vector
induced apoptotic cell death in CT26 subcutaneous tumors, and
abundant apoptosis induced by intratumoral IFN-a expression
may expose TAAs in large quantity and enhance the uptake of
released TAAs by DCs. Moreover, recent data have shown that
type I IFN itself can act as an important signal for differentiation
and maturation of DC: DCs generated after a few days of treat-
ment with IFN-a showed the mature phonotype.(4,27) It is known
that maturation of DCs is associated with up-regulation of the
co-stimulatory molecules, and enhancement of their antigen-pre-
senting function.(28) In this study also, the CD11+ cells isolated
from regional sites of mice treated by intratumoral IFN gene
transfer showed up-regulations of CD40, CD80, and CD86
(Fig. 5b) and the enhancement of antigen-presentation capacity
(Fig. 5c). Finally, TAA-specific T cells activated by DCs could
efficiently infiltrate into the CT26 tumors, leading to antitumor
effect. Therefore, the effective apoptosis induction and direct
immunomodulatory effect of IFN-a on DCs may contribute to
the observed augmentation of the tumor specific immunity.
Intravenous administration of an adenovirus results in gene
delivery primarily to the liver.(29,30) We previously reported a
significant production of IFN-a in the liver after an intravenous
injection of 1 · 107 of an IFN-a-expressing adenovirus vector
in the dimethylnitrosamine-induced cirrhotic rat, but no IFN-a
was detected in the serum.(31) The transgene expression was
mainly observed in the fibrous septa but not in hepatocytes in a
cirrhotic liver, whereas it was detected in septa as well as in
hepatocytes in the normal rats.(31) In this study, we intrave-
nously injected 1 · 108 PFU of Ad-mIFN to examine the biodis-
tribution of IFN-a expression in various mice organs (Fig. 1c).
The difference in the amount of the injected virus and theNarumi et al.histopathology of the liver may be the reason that high IFN-a
levels were sustained in the serum in this study.
It is well known that a systemic administration of IFN-a pro-
tein often induces severe adverse effects such as flu-like symp-
toms, leucopenia, liver dysfunction, and mental depression.(32)
With respect to the safety of a local IFN-a gene therapy, it is
noteworthy that the intratumoral IFN-a gene transfer showed
very limited general toxicity such as an elevation of hepatic
enzymes, since the IFN-a concentration in the serum was
approximately 6–68-fold lower in the intratumorally Ad-mIFN-
injected mice compared with the intravenously Ad-mIFN-
injected mice (Fig. 1b). The apparent difference in the IFN-a
concentration between the tumor and serum is an important
finding especially from the viewpoint of safety of local IFN-a
gene therapy. As one of the reasons for a little leakage of the
IFN-a protein from the tumors into blood circulation, we
recently reported that extracellular matrix proteins such as
fibronectin in tumors directly interact with IFN-a and retain the
cytokine.(23)
In summary, our preclinical study suggests that a regional
adenovirus-mediated gene transfer of IFN-a is one of the prom-
ising new approaches to cancer. The strategy may deserve an
evaluation in a future clinical trial for intractable cancer.
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